New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

"Piramal Pharma announces $90m investment to expand US sites" was originally created and published by Pharmaceutical ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

Pyxis Oncology is providing this information in accordance with Nasdaq Listig Rule 5635 (c) (4).